Heart Disease Treatment Breakthrough

... disease related illnesses that can cause heart attacks and stroke. Dozens of research studies ... of plaque in the arteries that can lead to heart attacks and stroke. Lycopene is the potent ... which is the damage that ends up causing heart attacks and strokes - this can potentially extend life ...

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

... liver cancer and kidney failure. Acute porphyric attacks can be life-threatening. AIP affects 1 per ... therapy completely prevented the occurrence of attacks and significantly ameliorated the neuropathy that ... protein in order to prevent acute porphyric attacks and their complications. About Amsterdam ...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

... prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. In February 2009, ... for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze would be the first ... the use of C1-INH for the treatment of acute attacks of hereditary angioedema due to C1 inhibitor ...

Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma

... of life measurements, reductions in asthma attacks (severe exacerbations) and emergency room visits ... the Alair System. "The reduction in asthma attacks and improvements in quality of life are ... sham controls 32% reduction in asthma attacks 84% reduction in emergency room visits ...

New Aspirin Recommendation Can Help Prevent Heart Attacks & Strokes, Says Partnership for Prevention

... value of regular aspirin use in preventing heart attacks and strokes among many adults, the head of ... that regular aspirin use reduces first heart attacks in men and first strokes in women. The ... appropriate use of aspirin to prevent heart attacks and strokes. Dr. Michael Pignone, who is a ...

Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms

... deciding whether to use aspirin to prevent heart attacks or strokes, according to new recommendations from ... good evidence that aspirin decreases first heart attacks in men and first strokes in women. The more ... should use aspirin to reduce their risk for heart attacks when the benefits outweigh the harms for ...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE). The supplemental ... 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. ... Cinryze closer to the patients who suffer acute attacks of hereditary angioedema," commented Vincent ...

Seniors Can Be Heartened by New Study on Statins

... we prevent heart disease." About half all heart attacks and strokes occur in people who do not have ... of a statin called rosuvastatin can prevent heart attacks and deaths in that group - people who would not ... heart disease. At this age, initial heart attacks tend to be more fatal than those suffered at ...

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

... the date of analysis. Patients suffering acute attacks of HAE who were treated with Cinryze experienced ... the subjects in this study treated for laryngeal attacks required hospitalization or intubation. The ... treated all of the types of acute HAE attacks seen during the trial," said Bruce Zuraw, MD, ...

Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

... Long-term benefits of preventing heart attacks highlighted in new study presented ... attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge. A new ... through a process called atherosclerosis. Heart attacks are a major manifestation of coronary ...

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

... for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary ... by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 ... Cinryze significantly decreased the number of HAE attacks compared to placebo. The trial had a crossover ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), ... who were managed with PCI. New or recurrent heart attacks were classified according to the ESC Universal ... significantly reduced spontaneous (Type 1) heart attacks by 29 percent compared with clopidogrel (2.5 ...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

... endpoint of cardiovascular death, non-fatal heart attacks or non-fatal stroke by 19 percent more than ... TIMI major bleeding events, but 23 fewer heart attacks in patients taking prasugrel compared ... syndromes (ACS), which is comprised of heart attacks and unstable angina (chest pain), affects more ...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

... for the symptomatic treatment of acute attacks of hereditary angioedema (HAE). HAE is a ... by unpredictable recurring swelling attacks in the hands, feet, face, larynx, and abdomen. It ... face, hands, and feet can be disfiguring, while attacks in the gastrointestinal tract result in severe ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the ... sufferers treating nearly 30,000 migraine attacks in clinical studies. The product is expected to ... study treated an average of five migraine attacks per month with Treximet. Migraines Impact ...

CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

... proposed indication is for the treatment of acute attacks in patients with HAE. Currently, there are no ... and/or the larynx. Patients who have abdominal attacks can experience episodes of severe pain, diarrhea, ... caused by swelling of the intestinal wall. attacks that involve the face and larynx can result ...

Interview of the Vice President

... strategy after 9/11. We used to treat terrorist attacks as a law enforcement problem. We went out and ... So one of the guys who helped organize the attacks on the World Trade Center is doing life out ... for our success at defeating all further attacks that have been launched against the United States ...

CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

... to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, ... in time to onset of relief of symptoms of HAE attacks compared to placebo (p= 0.003, one sided). ... the world who live with the burden of acute HAE attacks without approved treatment," said Timothy Craig, ...

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

... their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone. TRILIPIX is the first and only ... their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone. Important Safety Information ...

Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research

... been used to open up blocked blood vessels in the heart to prevent heart attacks and in the neck to prevent strokes. More recently stents have been used in the heart to treat occurring heart attacks by opening up the blocked arteries. This early research suggests stents ...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

... in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared ... effects on some of the secondary endpoints including the number of attacks of migraine headache and the number of auras followed by any headache. All ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... alprazolam). Alexza is developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In June 2008, the Company announced the ... and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates ...

Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy

... and 5,044 subjects on non-abacavir HAART. Overall, less than 30 heart attacks had been reported across the abacavir and non-abacavir groups and no ... 1,000 people in the non-abacavir HAART. Further, the frequency of heart attacks was 1.1 per 1,000 people in the abacavir HAART and 1.4 per 1,000 people in ...

FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel

... Acute coronary syndromes, which comprises heart attacks and unstable angina (chest pain), affects more than 1.4 million people in ... currently available treatments, 320,000 people experience recurrent heart attacks each year.(2) About prasugrel Daiichi Sankyo Company, Limited (TSE: ...

First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System

... interest may go a long way in providing information to help prevent heart attacks in the near future." Coronary artery disease, which causes heart attacks and chest pain, is the single leading cause of death in America, according ...

Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients

... product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony ... and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates ...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

... (Staccato alprazolam) is being developed for the acute treatment of panic attacks associated with panic disorder. Alexza is conducting a Phase 2a ... and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

... is a debilitating, yet common neurological disorder characterized by attacks of severe headache and autonomic nervous system dysfunction. Two doses of ... and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates ...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

... alprazolam) is being developed for the acute treatment of panic attacks associated with panic disorder. Alexza is conducting a Phase 2a ... headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the ...

A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females

... patients ranging from 22-57 years of age. The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of 2.8 +/- 1.3 attacks per month. The subjects were randomized in a ratio of 4:1: treatment to ...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

... the Taxus Stent (p=0.14). The rate of Q-wave myocardial infarction (heart attacks that involve the full thickness of the heart wall) was 0.0 percent for the ... In addition, the rates of non-Q wave myocardial infarctions (heart attacks that do not involve the full thickness of the heart wall) were 4.8 percent ...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... Atherosclerosis can lead to the blockage of arteries that commonly support the heart, brain, kidneys and extremities, and cause blood clots, heart attacks and stroke. Published in the American Society for Reproductive Medicine's Menopausal Medicine , KLRI publications findings were twofold ...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

... for measuring impairment in MS. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic, progressive, often disabling disease that attacks the central nervous system(ii). MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, ...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

... to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... glucose levels may be easier to control. About Type 1 Diabetes Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. The symptoms associated with type 1 diabetes can appear suddenly and leave a person ...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

... known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must ...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

... patient population. The BARI-2D trial set out to evaluate whether OMT alone or OMT plus revascularization is better in preventing death and heart attacks in a small, relatively healthy subset of diabetic patients with heart disease. The medical guidelines have never suggested PCI could achieve the ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... (154 events or 6.9 percent versus 165 events or 7.4 percent) (hazard ratio=0.93, 95 percent confidence interval=0.74 to 1.15) More heart attacks (64 out of 2,220 patients or 2.9 percent versus 56 out of 2,227 patients or 2.5 percent) (hazard ratio=1.14, 95 percent confidence interval=0.80 to ....

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... included life-threatening and fatal bleeding.(3) About Acute Coronary Syndromes Acute coronary syndromes, which is comprised of heart attacks and unstable angina (chest pain), affects nearly 1.5 million people in the United States annually.(4) Coronary heart disease, which can result in ...